Strategic Leadership Recent C-suite appointment of Olav Hellebø as CEO signals a potential shift in strategic direction and fundraising approach, presenting an opportunity to engage executive-level discussions on partnership, licensing, or large-scale collaboration in retinal disease therapeutics.

Clinical Advantage Lead asset EXN407 has shown potential as the first topical treatment for retinal vascular diseases, with favorable signals in a Phase Ib/IIa trial for diabetic macular edema, positioning Exonate to approach ophthalmology-focused payers and clinics with a novel, non-invasive option.

Early Stage Funding With funding of approximately $12M and sub-$1M revenue, Exonate is likely seeking partnerships or strategic investors to advance late-stage trials or commercialization, making it a viable target for co-development deals, grants, or equity investments.

Collaborative History Past Janssen collaboration on eye-drop RNA therapeutics indicates a precedent for big-pharma partnerships in retinal disease; this suggests a strong template for future licensing or collaboration discussions with Exonate.

Market Readiness Focused on retinal vascular diseases such as diabetic retinopathy and diabetic macular edema, Exonate’s niche aligns with a growing market for non-invasive, topical therapies, offering potential entry points with ophthalmology clinics, specialty pharmacies, and payer networks seeking innovative treatment options.